Allergan sues Valeant, Pershing Square for securities fraud
This article was originally published in Scrip
Executive Summary
Allergan is suing Valeant Pharmaceuticals and Pershing Square Capital Management for insider trading and misleading disclosures to investors in an increasingly bitter battle between a company that wants to stay independent and a competitor that wants to force a merger – a competitor that apparently has wanted to buy Allergan for at least two years.